Global Clostridioides Difficile Infection Treatment Market, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others (late phase drugs, etc.)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 893.4 Million in 2023 and is expected to exhibit a CAGR of 7.13% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing demand of the microbiome therapeutics for treating recurrent clostridioides difficile infection (CDI) has eventually lead to rise the production of microbiome therapeutics in the market. Henec, market players are engaged in adopting inorganic strategies such as agreements to develop microbiome therapeutics. For instance, in July 2021, Seres Therapeutics, a biotechnology company, entered into a strategic agreement with Nestlé Health Science S.A., a consumer product company, to jointly sell in the U.S. and Canada the former's experimental medication, SER-109, for recurrent Clostridioides difficile infection (CDI).
Global Clostridioides Difficile Infection Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
COVID-19 had a negative impact on the global clostridioides infection treatment market, due to the stringent regulatory laws of the COVID 19 the manufacturers faced a decline and shortage of the raw material and disruption in the clinical trial for manufacturing drugs in the treatment of the clostridioides difficile infection. For instance, in September 2021, according to the data published by the National Center for Biotechnology Information, the raw material supply was disrupted due to the acute stress of the COVID-19 pandemic had laid bare a series of long-term weaknesses in the U.S. public health system, including the increased in the demand of essential medications. The virus produced unprecedented shifts in the supply of raw materials, while simultaneously introducing new uncertainties about the production and distribution of pharmaceutical products. COVID-19-related shortages extended beyond antivirals to include a range of drugs broadly used in intensive care and general hospital management.
These shortages point to serious susceptibility in the pharmaceutical supply chain that compromises readiness for new waves of the current pandemic and crises that are expected soon. Because drug inventories are confidential, it was not possible to ascertain whether scarce resources are being distributed equitably and to prioritize areas and facilities of higher demand. This acute stress reveals a series of chronic weaknesses in pharmaceutical production, distribution, regulation, and oversight, which need to be remedied—and remedied soon—if the U.S. were to emerge from the present pandemic.
Furthermore, the pandemic resulted in the postponement of the ongoing clinical trials due to several restrictions and compulsions exhibited by the government of various countries. Due to the significant financial commitment (US$ 20–50 million per study), effective and timely management of clinical trial operations is essential for academic institutions and the pharmaceutical industry. Large trial centers also frequently operate many trials at once, enrolling thousands of participants at different locations throughout the world. Therefore, this pandemic interferes with operational decision-making, and planning, and produces operational gaps that may have a substantial negative impact on patient safety and financial costs if treatment is interrupted. The quarantine/isolation lead to deviations intended to remove a research participant’s immediate apparent threats.
Global Clostridioides Difficile Infection Treatment Market: Key Developments
In November 2022, Ferring Pharmaceuticals, a pharmaceutical company, announced that a single dose of RBX2660 demonstrated superiority to placebo as a treatment to reduce the recurrence of Clostridioides difficile infection (CDI) after standard-of-care antibiotic treatment in a Bayesian analysis model, and the results of this pivotal Phase 3 PUNCH CD3 clinical trial were published in the journal Drugs. An innovative live biotherapeutic based on the microbiota called RBX2660 is being researched for its potential to lessen recurrent clostridioides difficile infection (rCDI) following antibiotic therapy.
In October 2021, Vedanta Biosciences, a clinical-stage company, announced positive results for the Phase 2 clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent C. difficile infection (CDI) in high-risk patients, met its primary endpoint of preventing disease recurrence through Week 8.
In October 2022, Summit Therapeutics Inc., a biotechnology company, presented an oral podium presentation of the Ri-CoDIFy Trial at IDWeek 2022. Ri-CoDIFy is used in the treatment of the recurrence of clostridioides difficile infection .
Browse 35 Market Data Tables and 30 Figures spread through 182 Pages and in-depth TOC on “Global Clostridioides Difficile Infection Treatment Market”- Forecast to 2030, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others (late phase drugs, etc.)), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Clostridioides Difficile Infection Treatment Market:
- The global clostridioides infection treatment market is expected to exhibit a CAGR of 7.13% during the forecast period. The increasing research and development activities by the key players in the market is expected to drive the growth of the global clostridioides infection treatment market over the forecast period. For instance, in January 2020, Pfizer Inc., a pharmaceutical company, initiated the clinical trial study for the named CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial) for the prevention of C diff infection (CDI).
- In terms of route of administration, the oral segment is estimated to hold a dominant position in the global clostridioides infection treatment market over the forecast period. Owing to increasing research and development activities for the development of oral medication used in the treatment of Clostridioides difficile infection recurrence. For instance, in September 2021, Lumen Bioscience, a biopharmaceutical company, initiated the Phase 1 trial of LMN-Cdiff01, an orally delivered investigational biologic for the treatment and prevention of recurrent C. difficile infection (CDI).
- Major players operating in the global clostridioides difficile infection treatment market include Novartis AG, Baxter, ANI Pharmaceuticals, Inc., Mylan N.V., Akorn, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., B. Braun Medical Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical., Apotex Inc., AbbVie Inc., Ferring Pharmaceuticals, Fresenius Kabi USA., Pfizer Inc., Strides Pharma Science Limited., Sanofi., AstraZeneca., Eli Lilly and Company., Actelion Pharmaceuticals Ltd., and Astellas Pharma
